Home > Oncology > ASCO 2019 > Gastrointestinal Cancers > Neoadjuvant chemotherapy as a potential treatment option in colon cancer

Neoadjuvant chemotherapy as a potential treatment option in colon cancer

Presented By
Dr Matthew T. Seymour, National Institute for Health Research Clinical Research Network, England
Trial
FOxTROT
Medical writer: Muriel Cunningham Neoadjuvant chemotherapy (NAC) resulted in histologic regression and downstaging and decreased the rate of incomplete resections among patients with operable colon cancer, according to results of the FOxTROT trial presented by Matthew T. Seymour, MD, of the National Institute for Health Research Clinical Research Network, on June 1. The objectives of FOxTROT were to determine if NAC administration prior to surgery improves disease-free survival among patients with colon cancer. In addition, a substudy evaluated whether adding panitumumab to preoperative NAC for patients whose disease harbored wildtype KRAS would increase NAC anti-tumour activity (Abstract 3504). Patients with operable, nonobstructed, radiologically staged T3 or T4 (N0-2) colon cancer without metastases were randomly assigned 2:1 to either the NAC group or the control group. Patients in the NAC group received 6 weeks of FOLFOX followed by surgery and ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on